TERMINAL COMPONENT OF COMPLEMENT (C9) IN CEREBROSPINAL-FLUID OF PATIENTS WITH MULTIPLE-SCLEROSIS
TERMINAL COMPONENT OF COMPLEMENT (C9) IN CEREBROSPINAL-FLUID OF PATIENTS WITH MULTIPLE-SCLEROSIS
复制标题
DOI：
10.1016/s0140-6736(84)90298-8
复制
发表时间：
1984-01-01
期刊：
影响因子：
168.9
通讯作者：
COMPSTON, DAS
中科院分区：
文献类型：
--
作者：
MORGAN, BP;CAMPBELL, AK;COMPSTON, DAS
应用免疫放射分析法测定了35例多发性硬化患者和55例其他神经系统疾病对照者脑脊液和血浆中补体末端成分（C9）的浓度。在多发性硬化症患者中CSF C9浓度有非常显著的降低（0.26 ± 0.25）。0.02μ g/ml）与对照组（1.52 ± 0.05 μ g/ml）相比，0.20μ g/ml; P <0.0005）。作为单一蛋白测量，C9似乎比CSF IgG更有助于临床诊断;在两组患者之间，C9指数也比IgG指数更好。多发性硬化症患者CSF C9浓度降低意味着由于膜攻击复合物的形成导致C9消耗，这可能介导髓鞘损伤并导致更广泛但可逆的功能丧失;这是该疾病的短暂症状特征。
An immunoradiometric assay was used to measure the concentration of the terminal component of complement (C9) in CSF and plasma from 35 patients with multiple sclerosis and 55 controls with other neurological diseases. There was a highly significant reduction in CSF C9 concentration in patients with multiple sclerosis (0.26 .+-. 0.02 .mu.g/ml) compared with controls (1.52 .+-. 0.20 .mu.g/ml; P < 0.0005). As a single protein measurement C9 seemed to be more useful as an aid to clinical diagnosis than CSF IgG; the C9 index was also a better discriminator than IgG index between the 2 groups of patients. Reduced CSF C9 concentration in patients with multiple sclerosis implies C9 consumption due to formation of membrane attack complexes, which could mediate myelin damage and cause more widespread but reversible loss of function; this accounts for the transient symptoms characteristic of the disease.